Array BioPharma Inc. (NASDAQ:ARRY) Issues Quarterly Earnings Results

Xavier Trudeau
Août 13, 2017

Ack Asset Management Llc acquired 35,000 shares as Air Transport Services Group (ATSG)'s stock rose 33.68%. The hedge fund held 4.99M shares of the major pharmaceuticals company at the end of 2016Q4, valued at $43.83 million, down from 6.46 million at the end of the previous reported quarter. About shares traded. Graham Corporation (NYSE:GHM) has risen 28.00% since August 10, 2016 and is uptrending. Constellation Brands, Inc. (NYSE:STZ) has risen 17.20% since August 10, 2016 and is uptrending. It has outperformed by 54.16% the S&P500. Quantbot Technologies LP now owns 14,523 shares of the biopharmaceutical company's stock valued at $129,000 after buying an additional 1,423 shares during the last quarter. Therefore 75% are positive. The lowest price the stock reached in the last trading day was $8.1 and compares with the $3.1 52-week low. The stock rose 0.46% or $0.04 reaching $8.7 per share. BidaskClub cut shares of Array BioPharma from a "sell" rating to a "strong sell" rating in a research note on Wednesday, July 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.04. Ontario - Canada-based Manufacturers Life Insur Company The has invested 0% in Array Biopharma Inc (NASDAQ:ARRY). The company was maintained on Wednesday, August 9 by Cantor Fitzgerald. On average, equities analysts predict that Array BioPharma Inc. will post ($1.00) earnings per share for the current fiscal year. The rating was initiated by Suntrust Robinson with "Buy" on Friday, June 3. The firm now has a buy rating on the biopharmaceutical company's stock. Cantor Fitzgerald set a $13.00 price target on Array BioPharma and gave the company a "buy" rating in a research note on Wednesday. As per Monday, September 26, the company rating was maintained by Piper Jaffray. The rating was initiated by SunTrust with "Buy" on Friday, June 3. Carbonite had 8 analyst reports since September 21, 2015 according to SRatingsIntel. Analyst rating score as outlined on Finviz rated on a 1 to 5 scale. Cowen & Co has "Buy" rating and $1400 target. The firm has "Buy" rating given on Wednesday, May 31 by Mizuho. Barclays Capital upgraded the stock to "Overweight" rating in Monday, May 22 report. On Friday, October 2 the stock rating was maintained by Argus Research with "Buy". Moreover, Massachusetts Financial Ma has 0% invested in Carbonite Inc (NASDAQ:CARB) for 48,372 shares. American Gp owns 10,223 shares or 0% of their USA portfolio. Foot Locker Inc (NYSE:FL) was reduced too.

About 320 shares traded. The stock has an average rating of "Buy" and a consensus target price of $11.54. It has outperformed by 159.81% the S&P500.The move comes after 8 months negative chart setup for the $1.41B company.

Since an alpha above 1 hints at more gains, investors can predict some further rally scope.

Investors sentiment decreased to 1.3 in Q4 2016.

By historical standards, Array BioPharma Inc. 36 funds opened positions while 55 raised stakes. Fisher Asset Mngmt Ltd Limited Liability Company reported 65,693 shares or 0% of all its holdings. The insider, LEFKOFF KYLE, now holds 6,585 shares of ARRY. Nationwide Fund Advisors owns 139,267 shares. Creative Planning reported 1,200 shares or 0% of all its holdings. Product Ptnrs Limited Liability Corp stated it has 527,919 shares. Axa reported 880,223 shares. 245,500 were reported by California Public Employees Retirement Systems. A total of 4.3 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 3.05 Million shares, while its relative volume stands at 1.41.

Media coverage about Array BioPharma (NASDAQ:ARRY) has trended somewhat positive recently, according to Accern. Putnam Invests Llc accumulated 225,763 shares.

Array BioPharma a biopharmaceutical firm focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The company has market cap of $1.48 billion. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). A negative earnings surprise will usually result in a decline in share price.

Since March 28, 2017, it had 0 insider purchases, and 2 insider sales for $633,150 activity. $89,351 worth of Carbonite Inc (NASDAQ:CARB) was sold by FOLGER ANTHONY.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

D'autres rapports CampDesrEcrues

Discuter de cet article